相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Immune Response in Multiple Sclerosis
Sofia Rodriguez Murua et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2022)
Phosphodiesterase-4 inhibitors: a review of current developments (2013-2021)
Zhihao Liu et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2022)
Rolipram Rescues Memory Consolidation Deficits Caused by Sleep Deprivation: Implication of the cAMP/PKA and cAMP/Epac Pathways
Ahmed Maher et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2022)
Novel Liposomal Rolipram Formulation for Clinical Application to Reduce Emesis
Leila Gobejishvili et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2022)
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking
Claire Lugnier et al.
BIOCHEMICAL PHARMACOLOGY (2021)
NCS 613, a PDE4 inhibitor, by increasing cAMP level suppresses systemic inflammation and immune complexes deposition in kidney of MRL/lpr lupus- prone mice
Issaka Yougbare et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2021)
Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors
Wesam S. Ahmed et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Effects of chronic inhibition of phosphodiesterase-4D on behavior and regional rates of cerebral protein synthesis in a mouse model of fragile X syndrome
Michael Rosenheck et al.
NEUROBIOLOGY OF DISEASE (2021)
Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial
Elizabeth M. Berry-Kravis et al.
NATURE MEDICINE (2021)
Update on the Pathogenesis and Therapy of Atopic Dermatitis
Huaguo Li et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2021)
The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors
Dean Paes et al.
PHARMACOLOGICAL REVIEWS (2021)
The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions
Shahin Shams et al.
FRONTIERS IN PHARMACOLOGY (2021)
Apremilast and psoriasis in the real world: A retrospective case series
Lauren Dozier et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review
April W. Armstrong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Advances in the Development of Phosphodiesterase-4 Inhibitors
Ting Peng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
Jonathan E. Phillips
FRONTIERS IN PHARMACOLOGY (2020)
Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
Chin Kook Rhee et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2020)
Systemic Lupus Erythematosus
Marianthi Kiriakidou et al.
ANNALS OF INTERNAL MEDICINE (2020)
Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
Mauro Giorgi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders
Abid Bhat et al.
PHARMACOLOGICAL RESEARCH (2020)
Evaluating Dermal Pharmacokinetics and Pharmacodymanic Effect of Soft Topical PDE4 Inhibitors: Open Flow Microperfusion and Skin Biopsies
Stefan Eirefelt et al.
PHARMACEUTICAL RESEARCH (2020)
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
Dave Singh et al.
RESPIRATORY RESEARCH (2020)
Comparative Effectiveness and Safety Between Milrinone or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock
Tyler C. Lewis et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2019)
Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease A Review
Craig M. Riley et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders
Mark E. Gurney et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting Phosphodiesterases-Towards a Tailor-Made Approach in Multiple Sclerosis Treatment
Melissa Schepers et al.
FRONTIERS IN IMMUNOLOGY (2019)
Multiple sclerosis - a review
R. Dobson et al.
EUROPEAN JOURNAL OF NEUROLOGY (2019)
Ibudilast Inhibits Chemokine Expression in Rheumatoid Arthritis Synovial Fibroblasts and Exhibits Immunomodulatory Activity in Experimental Arthritis
Felix I. L. Clanchy et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
Dave Singh et al.
RESPIRATORY RESEARCH (2019)
Inhibitors of phosphodiesterase as cancer therapeutics
Ting Peng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Phosphodiesterase 4 inhibitors
Rema Zebda et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Inhibitors of phosphodiesterases in the treatment of cough
Juraj Mokry et al.
RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY (2018)
Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: A systematic review and meta-analysis
Jian Luo et al.
RESPIROLOGY (2018)
Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC-MS/MS and its application to a PK study
Xuemei Liu et al.
BIOANALYSIS (2018)
Atopic dermatitis
Stephan Weidinger et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD
Dave Singh et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
R. J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Diagnosis and Management of Rheumatoid Arthritis A Review
Daniel Aletaha et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Diagnosis and Management of Atopic Dermatitis: A Review
Khalad Maliyar et al.
ADVANCES IN SKIN & WOUND CARE (2018)
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Heng Li et al.
FRONTIERS IN PHARMACOLOGY (2018)
Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers
Fabrizia Mariotti et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2018)
Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis
Masutaka Furue et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis
Alice C. Cheape et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis
Vic Ciaravino et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases
Laura Carzaniga et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease
Y. Zhou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Care management in amyotrophic lateral sclerosis
M. -H. Soriani et al.
REVUE NEUROLOGIQUE (2017)
Amyotrophic lateral sclerosis
Orla Hardiman et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives
Lazaros I. Sakkas et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook
Jusleen Ahluwalia et al.
DRUGS (2017)
Giemsa-stained pseudo-micronuclei in rat skin treated with vitamin D3 analog, pefcalcitol
Akira Takeiri et al.
GENES AND ENVIRONMENT (2017)
Huntington's Disease-Update on Treatments
Kara J. Wyant et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2017)
Fragile X syndrome: a review of clinical and molecular diagnoses
Claudia Ciaccio et al.
ITALIAN JOURNAL OF PEDIATRICS (2017)
Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis
D. M. Paton
DRUGS OF TODAY (2017)
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease
Jimmy Chong et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2017)
Oral Phosphodiesterase-4 Inhibitors for Chronic Obstructive Pulmonary Disease Super Exacerbators
Jadwiga A. Wedzicha
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
In vivo effective dibenzo[b,d]furan-1-yl-thiazoles as novel PDE-4 inhibitors
Gopalan Balasubramanian et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast
Andrea Chiricozzi et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
PDE4B as a Microglia Target to Reduce Neuroinflammation
Damien D. Pearse et al.
GLIA (2016)
Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies
L. T. Zane et al.
IMMUNOTHERAPY (2016)
Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study
Fuminori Ohba et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study
Jon M. Hanifin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Advances in the treatment of cutaneous lupus erythematosus
A. Kuhn et al.
LUPUS (2016)
Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders
C. Wu et al.
OBESITY REVIEWS (2016)
A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients
D. Singh et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2016)
Second Messengers
Alexandra C. Newton et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2016)
Roflumilast: a review of its use in the treatment of COPD
Jadwiga A. Wedzicha et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2016)
The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases
Verena Katharina Raker et al.
FRONTIERS IN IMMUNOLOGY (2016)
Psoriasis
Jacqueline E. Greb et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?
Torsten Witte
CLINICAL RHEUMATOLOGY (2015)
Protective role of theophylline and their interaction with nitric oxide (NO) in adjuvant-induced rheumatoid arthritis in rats
Rishi Pal et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
Artrite reumatoide do idoso e do jovem
Ariane Carla Horiuchi et al.
Revista Brasileira De Reumatologia (2015)
Topical tacrolimus for atopic dermatitis
Jade Cury Martins et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool
Nahid Eskandari et al.
JOURNAL OF RESEARCH IN PHARMACY PRACTICE (2015)
CHF6001 I: A Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-Inflammatory Activity and Suitable for Topical Pulmonary Administration
Nadia Moretto et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
P. H. Schafer et al.
CELLULAR SIGNALLING (2014)
Discovery and Early Clinical Development of 2-{6-[2-(3,5-Dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a Soft-Drug Inhibitor of Phosphodiesterase 4 for Topical Treatment of Atopic Dermatitis
Jakob Felding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory Diseases
Elisabetta Armani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The Role of Cyclic Nucleotide Signaling Pathways in Cancer: Targets for Prevention and Treatment
Alexandra M. Fajardo et al.
CANCERS (2014)
Clinical potential of apremilast in the treatment of psoriatic arthritis
Alberto Cauli et al.
IMMUNOTARGETS AND THERAPY (2014)
Phosphodiesterase 4-targeted treatments for autoimmune diseases
Neal Kumar et al.
BMC MEDICINE (2013)
NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production
Issaka Yougbare et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2013)
PDE4 as a target for cognition enhancement
Wito Richter et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
Characterization of the Cellular Activity of PDE 4 Inhibitors Using Two Novel PDE 4 Reporter Cell Lines
Frank Wunder et al.
MOLECULAR PHARMACEUTICS (2013)
Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD
Henrik Watz et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2013)
Use of NSAIDs in treating patients with arthritis
Leslie J. Crofford
ARTHRITIS RESEARCH & THERAPY (2013)
Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease
Ana Garcia-Osta et al.
ACS CHEMICAL NEUROSCIENCE (2012)
Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments
Therese Keravis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
A brief review of chronic obstructive pulmonary disease
James C. Hogg
CANADIAN RESPIRATORY JOURNAL (2012)
The phosphodiesterase-4 inhibitor rolipram reverses Aβ-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats
Chuang Wang et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2012)
Disease Progression in MRL/lpr Lupus-Prone Mice Is Reduced by NCS 613, a Specific Cyclic Nucleotide Phosphodiesterase Type 4 (PDE4) Inhibitor
Therese Keravis et al.
PLOS ONE (2012)
NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues
Issaka Yougbare et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2011)
Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane
Anne Crilly et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Anti-TNF Treatment in Rheumatoid Arthritis
Janina Geiler et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor
Anthony T. Nials et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Functionalized pyrazoles and pyrazolo[3,4-d]pyridazinones: Synthesis and evaluation of their phosphodiesterase 4 inhibitory activity
Pierfrancesco Biagini et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
P. H. Schafer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation
L. SEKUT et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Pooneh Salari-Sharif et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety
Alex B. Burgin et al.
NATURE BIOTECHNOLOGY (2010)
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
Fiona E. McCann et al.
ARTHRITIS RESEARCH & THERAPY (2010)
The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
Dave Singh et al.
RESPIRATORY RESEARCH (2010)
Discovery of selective PDE4B inhibitors
Kenji Naganuma et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis
Tsutomu Akama et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease
P. Rolan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Inhibition of cAMP Degradation Improves Regulatory T Cell-Mediated Suppression
Tobias Bopp et al.
JOURNAL OF IMMUNOLOGY (2009)
Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor
Hon-Wah Man et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis
Bibiana Bielekova et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease
Leila Gobejishvili et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2008)
Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides:: Identification of MK-0873, a potent and effective PDE4 inhibitor
Daniel Guay et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Phosphodiesterase 4 inhibitors in chronic obstructive pulmonary disease: a new approach to oral treatment
Graeme P. Currie et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
PDE4 inhibitors: current status
D. Spina
BRITISH JOURNAL OF PHARMACOLOGY (2008)
NF-κB in inflammatory bowel disease
I. Atreya et al.
JOURNAL OF INTERNAL MEDICINE (2008)
MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers
J. D. Boot et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2008)
Cyclic adenosine monophosphate is a key component of regulatory T cell mediated suppression
Tobias Bopp et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Epithelial NEMO links innate immunity to chronic intestinal inflammation
Arianna Nenci et al.
NATURE (2007)
Cilomilast: Orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease
Shaunta' D. Martina et al.
ANNALS OF PHARMACOTHERAPY (2006)
Sildenafil citrate for the treatment of pulmonary arterial hypertension
SA Antoniu
EXPERT OPINION ON PHARMACOTHERAPY (2006)
Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors
L. Wollin et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2006)
Phosphodiesterase-4 as a therapeutic target
MD Houslay et al.
DRUG DISCOVERY TODAY (2005)
Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats
HT Zhang et al.
PSYCHOPHARMACOLOGY (2005)
The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro
NA Jones et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2005)
Phosphodiesterase inhibitors for cognitive enhancement
GM Rose et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
Structural basis for the activity of drugs that inhibit phosphodiesterases
GL Card et al.
STRUCTURE (2004)
Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization
S Pérez-Torres et al.
EXPERIMENTAL NEUROLOGY (2003)
Inhibition of Aβ production and APP maturation by a specific PKA inhibitor
Y Su et al.
FEBS LETTERS (2003)
Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling
M Conti et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
[H-3]cAMP binding sites and protein kinase A activity in the prefrontal cortex of suicide victims
Y Dwivedi et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors
JE Souness et al.
IMMUNOPHARMACOLOGY (2000)
Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions
SH Soderling et al.
CURRENT OPINION IN CELL BIOLOGY (2000)
Phosphodiesterase 4 inhibitors, structurally unrelated to Rolipram, as promising agents for the treatment of asthma and other pathologies
V Dal Piaz et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2000)
Phosphodiesterase 4 inhibitors and the treatment of asthma - Where are we now and where do we go from here?
MA Giembycz
DRUGS (2000)
分享论文
